Search results for Anifrolumab

Anifrolumab Biosimilar – Anti-IFNAR1 mAb – Research Grade, ProteoGenix, PX-TA1332

Description of Anifrolumab Biosimilar - Anti-IFNAR1 mAb - Research Grade General information on Anti-IFNAR1[Homo sapiens] (Anifrolumab) Monoclonal Antibody Anifrolumab has been studied to treat Scleroderma. Anifrolumab, or MEDI546, is a human monoclonal antibody of IgG1 type. It is able to bind to interferon (IFN) alpha receptors 1 (IFNAR1). This bond blocks type I IFN signaling. Anifrolumab is carrying three mutations (L234F/L235E/P331S) in the heavy chain. Those mutations aim to reduce the cell surface Fc gamma receptor and potential Fc mediated effector function. Indeed, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are mechanisms depending on these parts. Anifrolumab is developed to treat systemic lupus erythematosus (SLE) and lupus nephritis. About Systemic Lupus Erythematosus (SLE) SLE is an autoimmune disease which is characterized by its chronicity and mustisystem affections. SLE is evolving by succession of inflammatory phases and remissions. Many evidences are showing the role of type I IFNs in the pathogenesis of this immunologic disease. Increased type I IFN expression and type I IFN-induced cell signalling correlate with SLE severity. Numerous genetic polymorphisms increase susceptibility to SLE by increasing type I IFN signaling. About interferons Type I IFNs family includes IFN-α subtypes, IFN-β, IFN-δ, IFN-ε, IFN-κ and IFN-ω. These interferons and their receptors, the IFN alpha receptors 1 (IFNAR1) and 2 (IFNAR2), form a IFNAR complex with specific functions. This complex is leading to tyrosine phosphorylation of signal transducer and activator of transcription 1 (STAT1) and 2 (STAT2). Once phosphorylated, STAT1 and STAT2 translocate with IFN regulatory factor 9 (IRF9) to the nucleus. Then, they drive IFN-stimulated response element (ISRE) activation. ISRE promotes transcription of multiple IFN-stimulated genes: which leads to the production of proinflammatory and immunomodulatory proteins involved in the host innate immune response to viral infection.

Anifrolumab, Abbexa, abx831291

Anifrolumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IFNAR1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Anifrolumab has been investigated for the treatment of Scleroderma.

Anifrolumab ELISA Kit, ProteoGenix, KPTX200

Description of Anifrolumab ELISA Kit Anifrolumab ELISA Kit: A Revolutionary Tool for Studying and Targeting Antibody-Mediated Diseases The Anifrolumab ELISA Kit is a cutting-edge scientific tool that has revolutionized the study and targeting of antibody-mediated diseases. This innovative kit allows for the precise measurement of anifrolumab, a monoclonal antibody that has shown great potential as a therapeutic target for a variety of autoimmune diseases. In this article, we will explore the structure, activity, and applications of the Anifrolumab ELISA Kit, and highlight its significance in the field of antibody research. Structure of the Anifrolumab ELISA Kit The Anifrolumab ELISA Kit is a highly specific and sensitive enzyme-linked immunosorbent assay (ELISA) kit designed for the quantitative determination of anifrolumab in various biological samples. The kit is composed of several components, including microtiter plates coated with a monoclonal antibody against anifrolumab, a standard solution of known anifrolumab concentration, and a detection antibody conjugated to an enzyme such as horseradish peroxidase (HRP). The kit also includes all necessary reagents and buffers for sample preparation, washing, and color development. The structure of the Anifrolumab ELISA Kit allows for the specific and sensitive detection of anifrolumab in a variety of biological samples, including serum, plasma, and cell culture supernatants. The use of monoclonal antibodies ensures high specificity, while the HRP-conjugated detection antibody allows for a colorimetric readout, making the kit easy to use and interpret. Activity of the Anifrolumab ELISA Kit The Anifrolumab ELISA Kit works on the principle of competitive ELISA, where the amount of anifrolumab present in a sample is inversely proportional to the color intensity produced. In simple terms, the more anifrolumab present in a sample, the less HRP-conjugated detection antibody will bind to the coated monoclonal antibody, resulting in a weaker color signal. This color signal is then measured using a spectrophotometer, and the concentration of anifrolumab in the sample can be determined by comparing it to the standard curve. The Anifrolumab ELISA Kit has a high sensitivity, with a lower limit of detection of 0.1 ng/mL. This means that even very low levels of anifrolumab can be accurately measured, making it a valuable tool for studying the pharmacokinetics and pharmacodynamics of this therapeutic antibody. The kit also has a wide dynamic range, allowing for the measurement of anifrolumab concentrations ranging from 0.2 to 100 ng/mL. Applications of the Anifrolumab ELISA Kit The Anifrolumab ELISA Kit has a wide range of applications in both basic research and clinical settings. In research, the kit can be used to measure anifrolumab levels in various biological samples, allowing for the evaluation of its pharmacokinetics, biodistribution, and clearance. This information is crucial for the development and optimization of anifrolumab as a therapeutic agent. In the clinical setting, the Anifrolumab ELISA Kit can be used to monitor anifrolumab levels in patients receiving treatment for autoimmune diseases such as systemic lupus erythematosus (SLE). By measuring anifrolumab levels over time, clinicians can assess the efficacy of treatment and make informed decisions about dosing and therapy duration. This can ultimately lead to improved patient outcomes. Moreover, the Anifrolumab ELISA Kit can also be used to screen potential patients for anifrolumab therapy, as well as to identify patients who may be developing resistance to the treatment. This can aid in the development of personalized treatment plans and improve the overall success

Anifrolumab ELISA Kit, Abbexa, abx395089

Anifrolumab ELISA Kit is a quantitative ELISA kit for detection of Anifrolumab.Anifrolumab is one of three anti-type-1 interferon agents currently under investigation as a potential treatment for systemic lupus erythematosus (SLE). Initial in vivo studies observed higher levels of serum interferon (IFN) in patients with autoimmune disease as opposed to those of healthy controls. Further genetic analyses identified a consistent upregulation of IFN gene signatures in peripheral mononuclear cells of SLE patients. This signature was inducible by IFN, repressed with glucocorticoids, and possibly correlated with disease severity. Therefore, specific IFN gene signatures have been used in clinical trials as diagnostic and pharmacodynamic biomarkers in SLE.

Anifrolumab Biosimilar - Research Grade, ichor.bio, ICH5130

Detects human IFNAR1

Research Grade Anifrolumab (HB823016), abinScience, HB823016